AMGN Form 4: Michael V. Drake Adds 121.4308 Shares, Ownership 4,699.03

Rhea-AI Filing Summary

Michael V. Drake, a director of Amgen Inc. (AMGN), reported the vesting and conversion of Restricted Stock Units into 121.4308 shares on 08/08/2025. The vested RSUs convert one-for-one into common stock and were reported at a purchase price of $0, reflecting compensation rather than an open-market trade. After the transaction his direct beneficial ownership is reported as 4,699.0291 shares. The reported amount includes 227 Dividend Equivalents credited on vested-but-deferred RSUs that are paid in shares under the Director Incentive Program and the Amgen Inc. 2009 Equity Incentive Plan.

Insights

Corporate Governance Expert

TL;DR Director RSUs vested and converted to 121.4308 shares, raising direct holdings to 4,699.0291 shares; routine director compensation disclosure.

The Form 4 shows an immediate vesting event under Amgen's Director Incentive Program with payment in shares at a reported price of $0, indicating compensation delivery rather than a market purchase. The filing documents inclusion of 227 dividend equivalents credited to vested-but-deferred RSUs and confirms direct ownership status. This is a standard Section 16 disclosure aligning director interests with shareholders through equity compensation.

Securities Analyst

TL;DR A director received 121.4308 vested RSU shares at $0; the transaction is administrative and unlikely to have immediate market impact.

The entry reports acquisition code "A" for 121.4308 common shares resulting from vested RSUs and lists the post-transaction beneficial ownership as 4,699.0291 shares (direct). The zero dollar price reflects issuance on vesting. The disclosure is routine for executive/director compensation and provides transparent, timely notice required under Section 16.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Drake Michael V

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CA 91320

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/08/2025		A		121.4308	A	$0	4,699.0291(1)(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

2. These shares include 227 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

	/s/ Michael V. Drake	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Michael V. Drake report on Form 4 for AMGN?

Acquisition of 121.4308 shares via vested Restricted Stock Units on 08/08/2025, reported at a price of $0.

How many shares does Michael V. Drake beneficially own after the reported transaction?

4,699.0291 shares (reported as direct beneficial ownership following the transaction).

Were these shares part of a director compensation program for AMGN?

Yes; the RSUs were granted pursuant to the Amgen Inc. 2009 Director Incentive Program and the Second Amended and Restated 2009 Equity Incentive Plan.

Do the reported shares include Dividend Equivalents?

Yes; the reported shares include 227 Dividend Equivalents credited on vested but deferred RSUs and paid in shares.

Did Michael V. Drake pay cash to acquire the reported shares?

No; the transaction price is reported as $0, reflecting conversion of vested RSUs into shares.